Europe
Single intravenous dose phase 1 trial showed that AIC649 was safe and well tolerated in all dose groups
Part 1 top-line data of the NOX-A12 trial to be presented at the September ‘Fourth International Cancer Immunotherapy Conference’
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.
Probiodrug AG today announces its financial results for the first six months of 2018 ending June 30.
Bone Therapeutics announces H1 results for 2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
As part of an earlier announced restructuring program, UK-based GlaxoSmithKline is laying off 650 staffers in the U.S. GlaxoSmithKline employees approximately 15,000 people in the U.S.
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
PRESS RELEASES